About the RECONNOITER Study Program
(Randomized Evaluation of the benefit of Cilnidipine ON the Nature, Observational Indices, Temperature changes and overall Effect in scleroderma and Raynaud’s Disease)
The RECONNOITER Study was a 64 patient prospective, double-blind, randomized Phase 2 trial designed to assess the safety and efficacy of AISA-021 (cilnidipine) in patients with scleroderma and secondary Raynaud’s. The study assessed the impact of treatment on a variety of endpoints including Raynaud symptoms, GI effects, pain and overall assessments of Systemic Sclerosis. The study was conducted in two parts, Part A, a Phase 2A parallel arm evaluated dose, safety, and efficacy, and was completed in 27 patients. It further evaluated the effect co-administering tadalfil, a PDE-V inhibitor. Part B, evaluated AISA-021 alone in 33 patients with SSc-RP and was formally powered as a Phase 2 randomized crossover design to demonstrate safety and efficacy of AISA-021 daily treatment.
Patients were recruited at two hospitals in Australia, which started in 2021 was completed in 2022, due to the DSMB stopping full planned enrollment because the drug was well tolerated and appeared more effective than current therapies. The decision was thus made to evaluate the drug versus placebo in a larger Phase 2 trial. This study, Part B, completed enrollment in late 2025. Part B confirmed the early efficacy signal seen in part B in treating Raynaud’s symptoms in patients with systemic sclerosis and ws very well tolerated, with adverse events almost indistinguishable from placebo-treated patients.
Based on the results of RECONNOITER-1, AISA Pharma plans to continue the development program and is targeting starting a pivotal international prospective multi-center placebo-controlled study in 2028.